REG - Sareum Holdings PLC - Exercise of Share Options and Director Dealings

Sareum HoldingsAnnouncement

02/11/2023 15:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231102:nRSB2402Sa&default-theme=true

RNS Number : 2402S  Sareum Holdings PLC  02 November 2023

Sareum Holdings PLC

("Sareum" or the "Company")

Exercise of Share Options and Director Dealings

Cambridge, UK, 2 November 2023 - Sareum Holdings plc (AIM: SAR), a
biotechnology company developing next generation kinase inhibitors for
autoimmune disease and cancer, announces that on 30 October 2023, Dr Tim
Mitchell, Chief Executive Officer, and Dr John Reader, Chief Scientific
Officer, each exercised options over 95,040 ordinary shares of 1.25 pence each
("New Ordinary Shares") in the Company (the "Options"), at an exercise price
of 30 pence per New Ordinary Share, for an aggregate consideration of
£57,024.

The Options were granted on 18 December 2013, under the Sareum Holdings plc
Enterprise Management Incentives Option Agreement, and were due to lapse on 17
December 2023.

On exercise, Dr Mitchell and Dr Reader noted their intention to sell a
proportion of such New Ordinary Shares in the market on receipt, partly in
order to compensate for the cost and tax liabilities arising from the
exercise. A further announcement will be released in due course disclosing
such sales.

Following Admission (as defined below), Dr Mitchell's and Dr Reader's
resultant interests in the Company will be as follows:

 

 Director/           Date of transaction  Number of shares purchased via Option exercise  Purchase price  Total shares held  Percentage of issued share capital

PDMR
 Tim Mitchell ((1))  30 October 2023      95,040                                          30p             1,104,561          1.57%

 John Reader ((2))   30 October 2023      95,040                                          30p             1,127,537          1.60%

(1) - Included within Tim Mitchell's total holding are 200,000 Ordinary Shares
held by his spouse.

(2) - Included withing John Reader's total holding are 66,666 Ordinary Shares
held by his spouse. Please note this record corrects the typographical error
in respect of John Reader's shareholding announced on 3 November 2021.

 

Admission

Application has been made to the London Stock Exchange for the 190,080 New
Ordinary Shares to be admitted to trading on AIM ("Admission") and it is
expected that Admission will become effective and trading will commence at
8.00 a.m. on 3 November 2023.

Following Admission, the total number of Ordinary Shares in issue will be
70,261,878 and the total number of voting rights will therefore be 70,261,878.
This figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest in, or a change to their interest in, the share capital of the
Company under the FCA's Disclosure and Transparency Rules.

For further information, please contact:

 Sareum Holdings plc

 Tim Mitchell, CEO                                   01223 497700

 Lauren Williams, Head of Investor Relations         ir@sareum.co.uk

 Strand Hanson Limited (Nominated Adviser)

 James Dance / James Bellman                         020 7409 3494

 Peel Hunt LLP (Joint Corporate Broker)

 James Steel / Patrick Birkholm                      020 7418 8900

 Hybridan LLP (Joint Corporate Broker)

 Claire Noyce                                        020 3764 2341

 ICR Consilium (Financial PR)

 Jessica Hodgson / Davide Salvi / Stella Lempidaki   020 3709 5700

 

PDMR Notification Forms

 

The information set out below is provided in accordance with the requirements
of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

 

 1.  Details of the person discharging managerial responsibilities / person closely
     associated
 a)  Name                                                         Tim Mitchell
 2.  Reason for the Notification
 a)  Position/status                                              Chief Executive Officer
 b)  Initial notification/amendment                               Initial notification
 3.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         SAREUM HOLDINGS PLC
 b)  LEI                                                          213800PKERN2DY8FFM72
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv)each place
     where transactions have been conducted
 a)  Description of the Financial instrument, type of instrument  Ordinary shares of 1.25p each in the share capital of Sareum Holdings plc
     Identification code                                          ISIN for Ordinary Shares: GB00B02RFS12
 b)  Nature of the Transaction                                    Exercise of Options to acquire ordinary shares
 c)  Price(s) and volume(s)                                       Price(s)  Volume(s)
                                                                  30p       95,040 acquired by way of an exercise of options

 d)  Aggregated information                                       Price(s)  Volume(s)

                                                            30p       95,040 acquired by way of an exercise of options
     -      Aggregated volume

     -      Price
 e)  Date of the transaction                                      30 October 2023
 f)  Place of the transaction                                     London Stock Exchange (AIM)

d)

Aggregated information

-      Aggregated volume

-      Price

 Price(s)  Volume(s)
 30p       95,040 acquired by way of an exercise of options

e)

Date of the transaction

30 October 2023

f)

Place of the transaction

London Stock Exchange (AIM)

 

 1.  Details of the person discharging managerial responsibilities / person closely
     associated
 a)  Name                                                         John Reader
 2.  Reason for the Notification
 a)  Position/status                                              Chief Scientific Officer
 b)  Initial notification/amendment                               Initial notification
 3.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         SAREUM HOLDINGS PLC
 b)  LEI                                                          213800PKERN2DY8FFM72
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv)each place
     where transactions have been conducted
 a)  Description of the Financial instrument, type of instrument  Ordinary shares of 0.025p each in the share capital of Sareum Holdings plc
     Identification code                                          ISIN for Ordinary Shares: GB00B02RFS12
 b)  Nature of the Transaction                                    Exercise of Options to acquire ordinary shares
 c)  Price(s) and volume(s)                                       Price(s)  Volume(s)
                                                                  30p       95,040 acquired by way of an exercise of options
 d)  Aggregated information                                       Price(s)  Volume(s)

                                                            30p       95,040 acquired by way of an exercise of options
     -      Aggregated volume

     -      Price
 e)  Date of the transaction                                      30 October 2023
 f)  Place of the transaction                                     London Stock Exchange (AIM)

d)

Aggregated information

-      Aggregated volume

-      Price

 Price(s)  Volume(s)
 30p       95,040 acquired by way of an exercise of options

e)

Date of the transaction

30 October 2023

f)

Place of the transaction

London Stock Exchange (AIM)

 

 

 

About Sareum

Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing
next generation kinase inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which
modify the activity of the JAK kinase family and have best-in-class potential.
Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801
is a potential treatment for a range of autoimmune diseases and has entered
Phase 1a/b clinical development with an initial focus on psoriasis.

Sareum has an economic interest in SRA737, a clinical-stage Chk1 inhibitor
which it originally developed in collaboration with several Cancer Research
UK-related organisations. SRA737 has shown promising safety and efficacy in
two Phase 1/2 clinical trials.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential
application for cancer immunotherapy.

Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market
of the London Stock Exchange, trading under the ticker SAR. For further
information, please visit the Company's website at www.sareum.com
(http://www.sareum.com)

- Ends -

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHDZMGMDZKGFZM